Post-transplant lymphoproliferative disorder (PTLD) is serious life-threating complication of transplantation. The clinical picture differs from lymphomas observed in the general population, with different

manifestation, histopathology, higher aggressiveness with involvement of sites beyond the primary lymph node, and poorer outcome.

The objective of the study was to present nine cases of PTLD observed in our centre among the kidney transplant recipient population and discuss the results with up-to-date literature. We performed a retrospective single-centre assessment of PTLD incidence in the cohorts of kidney transplant recipients followed by our centre. We found nine cases of PTLD, five men and four woman, aged from 26 to 67 years at the time of diagnosis (mean [SD] 48 [5] years), transplanted between 1997 and 2013.

The disease was diagnosed between 2002 and 2017, from 6 to 440 months after transplantation (mean [SD] 96 [137] months). A diffuse large B-cell lymphoma was found in seven cases early as well as late after transplantation, and two patients presented T-cell lymphoma. Five patients achieved complete remission with no relapses after 6 to 13 months of treatment. In three cases the remission was achieved by switching to mammalian target of rapamycin inhibitors (mTORi) only. Four recipients died from

2 weeks to 15 months after PTLD was diagnosed.

Although the diagnostic criteria of different forms of PTLD are commonly known, rapid and correct diagnosis is not easy. PTLD is a relatively a rare disease, so there are too few studies and little consensus on the optimal treatment.

中文翻译：

---

成人肾移植受者的移植后淋巴细胞增生性疾病：病例系列和文献复习

移植后淋巴细胞增生性疾病（PTLD）是严重的危及生命的移植并发症。临床表现不同于一般人群中观察到的淋巴瘤，具有不同的

表现，组织病理学，较高的侵袭性以及累及原发淋巴结以外的部位，并且预后较差。

该研究的目的是介绍在我们中心的肾脏移植受者人群中观察到的9例PTLD，并与最新文献讨论结果。我们对肾移植接受者队列中的PTLD发生率进行了回顾性单中心评估，其次是我们的中心。我们发现9例PTLD，五男四女，诊断时年龄从26岁至67岁（平均[SD] 48 [5]岁），于1997年至2013年之间移植。

在2002年至2017年之间，即移植后6到440个月（平均[SD] 96 [137]个月），诊断出该病。在移植的早期和晚期都发现了7例弥漫性大B细胞淋巴瘤，其中2例患者出现了T细胞淋巴瘤。5例患者在治疗6到13个月后完全缓解，无复发。在三种情况下，仅通过改用雷帕霉素抑制剂（mTORi）作为哺乳动物靶点即可达到缓解。

在诊断为PTLD之后的2周至15个月内，有4位接受者死亡。

尽管不同形式的PTLD的诊断标准是众所周知的，但快速而正确的诊断并不容易。PTLD是一种相对罕见的疾病，因此关于最佳治疗的研究太少，共识也很少。